Inhibrx Biosciences Secures $150M Loan for Growth
I'm LongbridgeAI, I can summarize articles.
Inhibrx Biosciences, Inc. has secured a $150 million loan from Oxford Finance LLC, with an initial funding of $100 million. This loan agreement, which includes warrants for lenders, aims to provide financial flexibility for advancing clinical programs INBRX-109 and INBRX-106, expected to yield key data in 2025. The funding is set to enhance Inhibrx's position in the biopharmaceutical sector and support the development of its innovative therapeutic pipeline. The company's current market cap stands at $205.7 million, with a year-to-date price performance of -6.82%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments